A detailed history of Alliancebernstein L.P. transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 54,780 shares of YMAB stock, worth $610,249. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,780
Previous 58,140 5.78%
Holding current value
$610,249
Previous $702,000 2.42%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.95 - $15.39 $33,432 - $51,710
-3,360 Reduced 5.78%
54,780 $719,000
Q2 2024

Aug 14, 2024

SELL
$11.6 - $17.25 $43,848 - $65,205
-3,780 Reduced 6.1%
58,140 $702,000
Q1 2024

May 14, 2024

SELL
$6.57 - $18.69 $5,321 - $15,138
-810 Reduced 1.29%
61,920 $1.01 Million
Q4 2023

Feb 14, 2024

SELL
$4.88 - $7.42 $71,047 - $108,027
-14,559 Reduced 18.84%
62,730 $427,000
Q3 2023

Nov 14, 2023

SELL
$4.86 - $7.23 $435,942 - $648,531
-89,700 Reduced 53.72%
77,289 $421,000
Q2 2023

Aug 15, 2023

BUY
$5.68 - $10.34 $64,468 - $117,359
11,350 Added 7.29%
166,989 $1.13 Million
Q4 2022

Feb 14, 2023

SELL
$3.0 - $15.17 $5.98 Million - $30.3 Million
-1,994,425 Reduced 92.76%
155,639 $759,000
Q3 2022

Nov 15, 2022

SELL
$13.96 - $19.67 $9.29 Million - $13.1 Million
-665,801 Reduced 23.64%
2,150,064 $31 Million
Q2 2022

Aug 15, 2022

SELL
$8.22 - $15.13 $1.26 Million - $2.32 Million
-153,294 Reduced 5.16%
2,815,865 $42.6 Million
Q1 2022

May 13, 2022

BUY
$6.55 - $17.42 $6.73 Million - $17.9 Million
1,026,825 Added 52.87%
2,969,159 $35.3 Million
Q4 2021

Feb 14, 2022

BUY
$15.51 - $29.31 $8.14 Million - $15.4 Million
524,525 Added 37.0%
1,942,334 $31.5 Million
Q3 2021

Nov 10, 2021

BUY
$27.47 - $37.31 $1.9 Million - $2.58 Million
69,213 Added 5.13%
1,417,809 $40.5 Million
Q2 2021

Jul 30, 2021

BUY
$25.45 - $37.64 $2.98 Million - $4.41 Million
117,258 Added 9.52%
1,348,596 $45.6 Million
Q1 2021

May 06, 2021

BUY
$29.16 - $51.96 $6.44 Million - $11.5 Million
221,019 Added 21.88%
1,231,338 $37.2 Million
Q4 2020

Feb 08, 2021

BUY
$37.86 - $54.26 $1.92 Million - $2.76 Million
50,803 Added 5.29%
1,010,319 $50 Million
Q3 2020

Nov 12, 2020

BUY
$35.13 - $43.62 $2.53 Million - $3.15 Million
72,119 Added 8.13%
959,516 $36.8 Million
Q2 2020

Aug 13, 2020

SELL
$23.66 - $49.53 $1.19 Million - $2.49 Million
-50,332 Reduced 5.37%
887,397 $38.3 Million
Q1 2020

May 14, 2020

BUY
$14.39 - $35.8 $1.34 Million - $3.34 Million
93,265 Added 11.04%
937,729 $24.5 Million
Q4 2019

Feb 18, 2020

BUY
$23.81 - $33.78 $1.88 Million - $2.66 Million
78,763 Added 10.29%
844,464 $26.4 Million
Q3 2019

Nov 14, 2019

BUY
$21.57 - $31.37 $464,747 - $675,898
21,546 Added 2.9%
765,701 $20 Million
Q2 2019

Aug 14, 2019

BUY
$19.51 - $28.31 $1.56 Million - $2.27 Million
80,149 Added 12.07%
744,155 $17 Million
Q1 2019

May 14, 2019

BUY
$18.21 - $26.21 $1.96 Million - $2.82 Million
107,668 Added 19.35%
664,006 $17.4 Million
Q4 2018

Feb 13, 2019

BUY
$15.41 - $28.92 $3.57 Million - $6.69 Million
231,348 Added 71.19%
556,338 $11.3 Million
Q3 2018

Nov 08, 2018

BUY
$24.0 - $26.97 $7.8 Million - $8.76 Million
324,990 New
324,990 $8.63 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.